Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.43 |
| ▸ | OGA | O60502 | 8/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440610 | 0.89 | CRHR1 (0.41) | OGAACHECRHR1 | |
| SCHEMBL21006718 | 0.89 | OGA (0.40) | TRPV4OGAACHESLC2A1 | |
| SCHEMBL18724037 | 0.89 | OGA (0.40) | OGAACHESLC2A1 | |
| SCHEMBL17386797 | 0.89 | OGA (0.40) | TRPV4OGAACHESLC2A1 | |
| SCHEMBL17412757 | 0.89 | CRHR1 (0.41) | OGAACHECRHR1 | |
| SCHEMBL21005961 | 0.89 | OGA (0.40) | OGAACHESLC2A1 | |
| SCHEMBL17400676 | 0.89 | CRHR1 (0.40) | TRPV4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL21301017 | 0.89 | CRHR1 (0.40) | TRPV4ACHEALDH1A1MAPTKDM4E | |
| SCHEMBL21006189 | 0.88 | OGA (0.39) | OGASLC2A1 | |
| SCHEMBL18724392 | 0.88 | OGA (0.39) | OGASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49111-E1 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2022-06-21 | — | — | US | disclosed |
| EP-3153511-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES | ASTELLAS PHARMA INC (JP) | 2019-05-15 | — | — | EP | disclosed |
| US-9951060-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-9844549-B2 | 2-aminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-12-19 | — | — | US | disclosed |
| US-20170290824-A1 | 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2017-10-12 | — | — | US | disclosed |
| US-20170197955-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-3153511-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-9562044-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002218-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, CHRM5 | TRPV4 23/4885OGA 2832/4885ACHE 184/4885 |
| US-20170197955-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, TRPM2 | TRPV4 24/4885OGA 2438/4885ACHE 157/4885 |
| US-20170290824-A1 | 2-AMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | CHRM3, CHRM2, TRPM2 | TRPV4 30/4885OGA 2653/4885ACHE 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.